Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (KURA) has announced the granting of inducement awards to six new employees as approved by the Company's Compensation Committee on March 3, 2025. The awards consist of nonstatutory stock options to purchase 190,000 shares of common stock under the Company's 2023 Inducement Option Plan.
The stock options were granted at an exercise price of $7.25 per share, matching the Company's closing sales price on March 3, 2025. The vesting schedule spans four years, with 25% of shares vesting after the first year, followed by monthly vesting of the remaining shares over 36 months, contingent on continued employment.
Kura Oncology (KURA) ha annunciato l'assegnazione di premi di incentivazione a sei nuovi dipendenti, come approvato dal Comitato per la Compensazione della Società il 3 marzo 2025. I premi consistono in opzioni su azioni non statutarie per l'acquisto di 190.000 azioni di azioni ordinarie nell'ambito del Piano di Opzioni di Incentivazione 2023 della Società.
Le opzioni su azioni sono state concesse a un prezzo di esercizio di $7,25 per azione, corrispondente al prezzo di chiusura delle vendite della Società del 3 marzo 2025. Il piano di maturazione si estende su quattro anni, con 25% delle azioni che maturano dopo il primo anno, seguite da una maturazione mensile delle azioni rimanenti nel corso di 36 mesi, a condizione di un impiego continuativo.
Kura Oncology (KURA) ha anunciado la concesión de premios de incentivo a seis nuevos empleados, como fue aprobado por el Comité de Compensación de la Compañía el 3 de marzo de 2025. Los premios consisten en opciones de acciones no estatutarias para comprar 190,000 acciones de acciones ordinarias bajo el Plan de Opciones de Incentivo 2023 de la Compañía.
Las opciones de acciones se otorgaron a un precio de ejercicio de $7.25 por acción, igualando el precio de cierre de ventas de la Compañía el 3 de marzo de 2025. El cronograma de adquisición se extiende por cuatro años, con 25% de las acciones adquiriéndose después del primer año, seguido de una adquisición mensual de las acciones restantes durante 36 meses, condicionado a la continuidad del empleo.
Kura Oncology (KURA)는 2025년 3월 3일 회사 보상 위원회에서 승인된 대로 여섯 명의 신규 직원에게 유인 보상을 부여한다고 발표했습니다. 이 보상은 회사의 2023 유인 옵션 계획에 따라 190,000주의 보통주를 구매할 수 있는 비법적 주식 옵션으로 구성됩니다.
주식 옵션은 주당 $7.25의 행사 가격으로 부여되었으며, 이는 2025년 3월 3일 회사의 종가와 일치합니다. 주식의 취득 일정은 4년에 걸쳐 있으며, 25%의 주식이 첫 해에 취득되고, 나머지 주식은 36개월에 걸쳐 매월 취득됩니다. 이는 지속적인 고용을 조건으로 합니다.
Kura Oncology (KURA) a annoncé l'octroi de primes d'incitation à six nouveaux employés, comme approuvé par le Comité de Rémunération de la Société le 3 mars 2025. Les primes consistent en des options d'achat d'actions non statutaires pour acquérir 190 000 actions ordinaires dans le cadre du Plan d'Options d'Incitation 2023 de la Société.
Les options d'achat d'actions ont été accordées à un prix d'exercice de 7,25 $ par action, correspondant au prix de clôture des ventes de la Société le 3 mars 2025. Le calendrier d'acquisition s'étend sur quatre ans, avec 25% des actions acquises après la première année, suivies d'une acquisition mensuelle des actions restantes sur 36 mois, sous réserve d'un emploi continu.
Kura Oncology (KURA) hat die Gewährung von Anreizprämien an sechs neue Mitarbeiter bekannt gegeben, die am 3. März 2025 vom Vergütungsausschuss des Unternehmens genehmigt wurden. Die Prämien bestehen aus nichtstatutarischen Aktienoptionen zum Kauf von 190.000 Aktien des Stammkapitals im Rahmen des Anreizoptionsplans 2023 des Unternehmens.
Die Aktienoptionen wurden zu einem Ausübungspreis von 7,25 $ pro Aktie gewährt, was dem Schlussverkaufspreis des Unternehmens am 3. März 2025 entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25% der Aktien nach dem ersten Jahr vesten, gefolgt von einer monatlichen Vestedung der verbleibenden Aktien über 36 Monate, abhängig von einer fortgesetzten Beschäftigung.
- Successful recruitment of 6 new employees indicating company growth
- Implementation of employee retention strategy through stock options
- Potential dilution of existing shareholders from 190,000 new stock options
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 190,000 shares of common stock to six (6) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors:
Patti Bank
Managing Director
(415) 513-1284
patti.bank@icrhealthcare.com
Media:
Alexandra Weingarten
Associate Director, Corporate Communications
& Investor Relations
(858) 500-8822
alexandra@kuraoncology.com
FAQ
What is the exercise price for KURA's new stock options granted on March 3, 2025?
How many shares of KURA stock are covered by the March 2025 inducement grants?
What is the vesting schedule for KURA's March 2025 inducement stock options?
How many employees received KURA stock option inducement grants in March 2025?
